PTK2 and lung carcinoma: Immunoblot in A549 lung cancer cells evidenced that concurrent inhibition of ERK5 and CDK5 cooperated in suppressing FAK activity as evidenced by the decreased phosphorylation of both FAKS910 and FAKS732 as well as FAKTyr397, which is essential for FAK full activation (Fig. 2F).